These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

435 related items for PubMed ID: 16385514

  • 1. Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease.
    Trad S, Amoura Z, Beigelman C, Haroche J, Costedoat N, Boutin le TH, Cacoub P, Frances C, Wechsler B, Grenier P, Piette JC.
    Arthritis Rheum; 2006 Jan; 54(1):184-91. PubMed ID: 16385514
    [Abstract] [Full Text] [Related]

  • 2. Determinants of morbidity and mortality of systemic sclerosis in Canada.
    Al-Dhaher FF, Pope JE, Ouimet JM.
    Semin Arthritis Rheum; 2010 Feb; 39(4):269-77. PubMed ID: 18706680
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study.
    Bérezné A, Ranque B, Valeyre D, Brauner M, Allanore Y, Launay D, Le Guern V, Kahn JE, Couderc LJ, Constans J, Cohen P, Mahr A, Pagnoux C, Hachulla E, Kahan A, Cabane J, Guillevin L, Mouthon L.
    J Rheumatol; 2008 Jun; 35(6):1064-72. PubMed ID: 18464307
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity.
    Michelfelder M, Becker M, Riedlinger A, Siegert E, Drömann D, Yu X, Petersen F, Riemekasten G.
    Clin Rheumatol; 2017 Feb; 36(2):381-390. PubMed ID: 28028682
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Interstitial lung disease associated with systemic sclerosis: what is the evidence for efficacy of cyclophosphamide?
    Bérezné A, Valeyre D, Ranque B, Guillevin L, Mouthon L.
    Ann N Y Acad Sci; 2007 Sep; 1110():271-84. PubMed ID: 17911442
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease.
    Launay D, Humbert M, Berezne A, Cottin V, Allanore Y, Couderc LJ, Bletry O, Yaici A, Hatron PY, Mouthon L, Le Pavec J, Clerson P, Hachulla E.
    Chest; 2011 Oct; 140(4):1016-1024. PubMed ID: 21474572
    [Abstract] [Full Text] [Related]

  • 13. Pulmonary arterial hypertension and severe pulmonary fibrosis in systemic sclerosis patients with a nucleolar antibody.
    Steen VD, Lucas M, Fertig N, Medsger TA.
    J Rheumatol; 2007 Nov; 34(11):2230-5. PubMed ID: 17937469
    [Abstract] [Full Text] [Related]

  • 14. Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status.
    Simeón-Aznar CP, Fonollosa-Plá V, Tolosa-Vilella C, Espinosa-Garriga G, Ramos-Casals M, Campillo-Grau M, García-Hernández FJ, Castillo-Palma MJ, Sánchez-Román J, Callejas-Rubio JL, Ortego-Centeno N, Egurbide-Arberas MV, Trapiellla-Martínez L, Gallego-Villalobos M, Sáez-Comet L, Velilla-Marco J, Camps-García MT, de Ramón-Garrido E, Esteban Marcos EM, Pallarés-Ferreres L, Hidalgo-Tenorio C, Sabio-Sánchez JM, Gómez-de la Torre R, Salvador-Cervello G, Rios-Blanco JJ, Gil-Aguado A, Vilardell-Tarrés M.
    Semin Arthritis Rheum; 2012 Jun; 41(6):789-800. PubMed ID: 22169458
    [Abstract] [Full Text] [Related]

  • 15. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.
    Mathai SC, Hummers LK, Champion HC, Wigley FM, Zaiman A, Hassoun PM, Girgis RE.
    Arthritis Rheum; 2009 Feb; 60(2):569-77. PubMed ID: 19180517
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Improved transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension and interstitial lung disease.
    Volkmann ER, Saggar R, Khanna D, Torres B, Flora A, Yoder L, Clements PJ, Elashoff RM, Ross DJ, Agrawal H, Borazan N, Furst DE, Saggar R.
    Arthritis Rheumatol; 2014 Jul; 66(7):1900-8. PubMed ID: 24729406
    [Abstract] [Full Text] [Related]

  • 18. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression.
    Goh NS, Veeraraghavan S, Desai SR, Cramer D, Hansell DM, Denton CP, Black CM, du Bois RM, Wells AU.
    Arthritis Rheum; 2007 Jun; 56(6):2005-12. PubMed ID: 17530640
    [Abstract] [Full Text] [Related]

  • 19. Increased plasma levels of adrenomedullin, a vasoactive peptide, in patients with end-stage pulmonary disease.
    Vizza CD, Letizia C, Sciomer S, Naeije R, Della Rocca G, Di Roma A, Musarò S, Quattrucci S, Gaudio C, Battagliese A, Badagliacca R, D'Erasmo E, Fedele F.
    Regul Pept; 2005 Jan 15; 124(1-3):187-93. PubMed ID: 15544858
    [Abstract] [Full Text] [Related]

  • 20. Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma.
    Garin MC, Highland KB, Silver RM, Strange C.
    J Rheumatol; 2009 Feb 15; 36(2):330-6. PubMed ID: 19208563
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.